Patients with CD30 positive DLBCL, primary refractory or in first relapse after R-CHOP or
R-CHOP-like therapy will receive brentuximab vedotin in combination with R-DHAP, followed in
responsive patients by high dose chemotherapy and ASCT.
Patients with primary refractory or relapse diffuse large B cell lymphoma (DLBCL) after
R-CHOP have a dismal prognosis. Only 25% long term survivors are observed after salvage with
high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). CD30
expression is observed in 30% of refractory/relapse DLBCL.
Monotherapy with brentuximab vedotin is effective in relapse CD30 positive DLBCL. The
addition of brentuximab vedotin to R-DHAP might improve the prognosis of these patients.
Treatment will consist of 3 cycles of brentuximab-vedotin in combination with R-DHAP. During
the phase I part the recommended dose level for this combination will be established. Cycles
will be given every 3 weeks.
Responsive patients will be treated with BEAM followed by ASCT. Total treatment duration is
approximately 16 weeks.
Subsequently patients will be followed until 5 years after registration.
Diffuse Large B-Cell Lymphoma,
diffuse large cell lymphoma,
diffuse large b cell lymphoma
Clinical Study Identifier
Stichting Hemato-Oncologie voor Volwassenen Nederland
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.